Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $41.9 million.

  • Anika Therapeutics' Total Non-Current Liabilities fell 1747.12% to $41.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.9 million, marking a year-over-year decrease of 1747.12%. This contributed to the annual value of $48.0 million for FY2024, which is 1722.48% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Total Non-Current Liabilities is $41.9 million, which was down 1747.12% from $39.3 million recorded in Q2 2025.
  • Anika Therapeutics' Total Non-Current Liabilities' 5-year high stood at $79.8 million during Q1 2021, with a 5-year trough of $39.3 million in Q2 2025.
  • In the last 5 years, Anika Therapeutics' Total Non-Current Liabilities had a median value of $57.3 million in 2023 and averaged $56.2 million.
  • Over the last 5 years, Anika Therapeutics' Total Non-Current Liabilities had its largest YoY gain of 2288.67% in 2021, and its largest YoY loss of 4833.29% in 2021.
  • Over the past 5 years, Anika Therapeutics' Total Non-Current Liabilities (Quarter) stood at $59.2 million in 2021, then increased by 6.72% to $63.2 million in 2022, then fell by 8.24% to $58.0 million in 2023, then decreased by 17.22% to $48.0 million in 2024, then dropped by 12.73% to $41.9 million in 2025.
  • Its Total Non-Current Liabilities stands at $41.9 million for Q3 2025, versus $39.3 million for Q2 2025 and $41.5 million for Q1 2025.